Head-to-head · Cost-Efficiency Index
Ondra Health vs Boston Medical Group
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Ondra Health
Value shoppers who want one of the lowest disclosed prices on both molecules without giving up nationwide access or pharmacy verification.
Visit Ondra HealthBoston Medical Group
Cost-first shoppers who want a clinician-run 12-week programme and can accept a price quoted as a range rather than a rate.
Visit Boston Medical GroupThe verdict
Ondra Health takes it, leading the Cost-Efficiency Index 90 to 59. A rare combination — near-rock-bottom pricing on both molecules, all-50 access, brand-name availability, and a LegitScript-verified pharmacy behind it. Boston Medical Group still earns a C — Cost-first shoppers who want a clinician-run 12-week programme and can accept a price quoted as a range rather than a rate.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the board). See how it stacks up: CoreAge Rx vs Ondra Health.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Ondra Health | Boston Medical Group |
|---|---|---|
| Cost-Efficiency Index | 90/100 | 59/100 |
| Semaglutide / mo | $93/mo | $199/mo (starting strength, rising with dose, compounded) |
| Tirzepatide / mo | $166/mo | Not disclosed |
| Semaglutide / yr (modeled) | $1,116 | $2,388 |
| Tirzepatide / yr (modeled) | $1,992 | — |
| Coverage | All 50 states | 7 states |
| Oral / sublingual | No | No |
| Brand-name access | Yes | Compounded only |
| Rank on the board | #2 | #247 |
Ondra Health
90/100Where the value is
- Among the lowest disclosed prices on the board — $93 semaglutide and $166 tirzepatide
- Available in all 50 states with both molecules published for clean cost modeling
- LegitScript-certified, and offers FDA-approved brand-name access alongside compounded
The tradeoffs
- A newer, lower-profile operator without CoreAge's long flat-price track record
- No oral/sublingual route
Boston Medical Group
59/100Where the value is
- An established medical group with a defined 12-week programme rather than an open-ended subscription
- The price range and the 12-week total are both published, once you reach the costs page
- Semaglutide is prescribed and dispensed under a compounded pathway with clinician oversight
The tradeoffs
- The published rate is a range by dose strength, $199 to $299, so the figure quoted is the floor rather than what a titrated patient pays
- The 12-week programme totals $699 including a telemedicine platform fee that is never itemised — about $233/mo all-in, not $199
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.